Become an IMR Panelist
IMR Logo

Infectious Disease Diagnostics Market - Size & Upcoming Industry Trends (2024-2032)

Infectious Disease Diagnostics Market by Product (Instruments (MRSA ,Streptococcus ,Clostridium Difficile ,VRE ,CRE ,Respiratory Virus ,Candida ,TB and Drug-resistant TB ,Gastro-intestinal Panel Testing ,Chlamydia ,Gonorrhea ,HPV ,HIV ,Hepatitis C ,Hepatitis B ,COVID-19 ,Others Infectious Diseases) ,Reagents,( MRSA ,Streptococcus ,Clostridium Difficile ,VRE ,CRE ,Respiratory Virus ,Candida ,TB and Drug-resistant TBGastro-intestinal Panel Testing ,Chlamydia ,Gonorrhea ,HPV ,HIV ,HepatitisC, ,Hepa

  • Report ID : 19474
  • Category : Diagnostics
  • Format :Excel formatPDF formatWord format
Request Sample

Infectious Disease Diagnostics Market Synopsis:

 Infectious Disease Diagnostics Market Size Was Valued at USD 26.74 Billion in 2023, and is Projected to Reach USD 33.10 Billion by 2032, Growing at a CAGR of 2.4% From 2024-2032.

The infectious disease diagnostics market can be defined as the segment of medical market dedicated to creating and implementing diagnostics, tests, kits, and associated technologies used for the identification, detection, and tracking of infectious diseases agents including bacteria, viruses, fungi, and parasites. These diagnostic solutions include molecular diagnostics, immunoassays and microbiology tests that allow healthcare professionals to diagnose infections early hence management. The market has an importance of regulating communicable diseases, enhancing patient experiences and promoting safety of the general population.

The infectious disease diagnostics market has grown remarkably over the years owing to looming fear of infectious diseases across the world and innovations in diagnosis. These are PCR assays, ELISA, rapid diagnostics tests, and next-generation sequencing tests among others. Infectious diseases including COVID-19, Influenza, HIV-AIDS and tuberculosis among others continue to increase globally, which calls for prompt diagnosis; this has fostered market growth.

Additionally, the increasing needs for point of care testing which provide immediate results to the patient location have moved the diagnostics industry to the next level. Other factors that have fueled this necessity are the rise in international and domestic tourists, growing concern in urban areas and antibiotic resilient bacteria the world over. In answer to these needs, companies are launching new product development researches to provide innovative diagnostic tools, enhancing the indicators of sensitivity, specificity, and time of the test. New technologies such as digital health, and AI in diagnostics are also predicted to transform the market because of the improvements in diagnostic output that get rid of human error.

The market is also affected by organizations’ expenditure on research into infectious diseases as well as the development of worldwide diagnostic protocols. Such organizations as the FDA and The European Medicines Agency bear significant responsibility concerning the safety and effectiveness of diagnostic products. The COVID-19 pandemic has benefited the market without a doubt, as there was a great need for fast and accurate diagnostic tools which led to the purchase of molecular and antigen-based tests. However, a number of constraints such as high diagnostic costs, inadequate infrastructure especially in developing world, and regulatory issues still remain the main barriers to market development.

Infectious Disease Diagnostics Market

Infectious Disease Diagnostics Market Trend Analysis:

Advancements in Molecular Diagnostics and Point-of-Care Testing

  • Recently, there has been a trend towards the molecular diagnosis and the POCT as primary trends in the IAM of infectious diseases. Conventional approaches to detecting and diagnosing pathogens include Microscopy and Culture, Immunological Methods, Biochemical Tests, Microbial Identification Method, Analytical Methods, Biophysical Methods, and Molecular Diagnostic Techniques which include PCR and NGS. These technologies are especially useful in conditions that be hard to diagnose using other methods such as TB, HIV and MDR TB. Increasing utilization of molecular diagnostic tests is caused by the application and technology requirements to obtain rapid results that facilitate treatment alternatives particularly in intensive care units.
  • Another trending innovation is in point-of-care testing in which diagnosis of the infections is done right at the patient site or nearby, a practice which did not require the sample to visit a laboratory center. POCT is especially most useful in situations where access and availability of sophisticated health facilities are greatly compromised such as in remote areas, rural or areas of less economic development. The recent advancement of portable, easy to operate devices that give results within a few minutes has made POCT the preferred method for a large number of providers. Moreover, the COVID-19 pandemic has further boosted the rapid diagnostics technology where governments and health stakeholders seek to develop and adopt easier-to-use, rapid antigen and molecular tests for the virus. This trend is expected to continue as healthcare systems globally seek for the ways in which test capacity can be enhanced, patient waiting reduced and diagnostic access enhanced.

 Expanding Market Potential in Emerging Economies

  • The market is well positioned to expand in the infectious disease diagnostics segment essentially because there is need for better diagnostics for infectious diseases in the emerging markets where the diseases are prevalent. The developed south Asian countries, south African countries, and Latin American countries are staring at spiking cases of communicable diseases of the malaria, tuberculosis, dengue, HIV types and recently, the Ebola and zika virus. However, such regions lack health care facilities and grossly lack most of the high-tech diagnostic solutions.
  • This is clearly a potential niche in which diagnostic players can come in and offer specific diagnostic solutions far more basic, cheap, and simple than what is now available in developed regions. RTDs, mhealth solutions and low-cost molecular diagnostic platforms could complement the deficiencies in disease detection, leading to faster intercessions and enhanced populace health in these areas. Also, rising usage of telemedicine and other digital healthcare service in these areas creates new window of opportunities for diagnosing and monitoring of infectious diseases from distance. Infectious disease diagnostics market is set to grow due to the emphasis of governments, NGOs, and international health organisations on system improvement within these regions.

Infectious Disease Diagnostics   Market Segment Analysis:

Infectious Disease Diagnostics Market is Segmented on the basis of Product, Technology, application, Test Location, and Region

By Product, Instruments segment is expected to dominate the market during the forecast period

  • Reagents dominated and hold 67.21% of the Global market in the year 2023. This can be can be attributed to the high volume usage of reagents and test kits for determination of the presence of infectious diseases. Also, the testing programs to diagnose COVID-19 to check SARS-CoV-2, infection rates are increasing the utilization of reagents. For example, as of May 2023, 449 tests collection devices for COVID-19 infection detection were approved by the U.S. FDA, of which there were 449 products available in the market and 116 products could be use as OTC or collecting samples at-home tests.
  • A system integration focus is becoming increased due to rapid innovation as a key factor to get a competitive advantage. For example, in May 2023, Hologic’s Panther Fusion SARS-CoV-2, influenza A & B, and RSV assay received the 510(k) clearance of the U.S. FDA. This assay is a molecular diagnostic test that can differentiate the four most prevailing respiratory virus: RSV, influenza A, influenza B, and SARS-CoV-2. It also shows that there is higher demands from the side of consumers in the software segment, which is a continuous process; usage in laboratories only. For instance some want cloud computing while others want concierge services and require a team of experts in software management. Currently, in January 2023, QIAGEN has recently launched EZ2 Connect MDx platform to advance the automation of sample processing capabilities.

By Technology, Immunoassay segment expected to held the largest share

  • Molecular diagnostics technology emerged to be the largest revenue generating market segment in 2023 at 35.76%. This is due to a vast market share by companies offering MDx techniques like PCR and NGS and higher testing efficacy. Additionally, the leading players are involved in the development of new offers for molecular diagnostics and enlargement of offerings. For instance, in April 2023, ELITechGroup revealed plans for its upcoming innovation: the launch of a high through put molecular diagnostics sample to result equipment.
  • On this basis, there will be a heightened demand in immunoassay technology for use in the required period. There is tremendous interest in creating and marketing immunoassay methods for consuming contagions on requestdue to the higher demand for rapid tests. For instance, in October 2023, F. Hoffmann-La Roche Ltd submitted a biologic license application BLA for Elecsys HTLV I/II assay intended as product for a test that uses a chemiluminescent enzyme immunoassay technology the test is designed to detect antibodies to HTLV-I and HTLV-II in human serum and plasma. The application of immunoassays for identification of various microorganisms infecting humans has been on the upward trend in the past years and is expected to rise further in the future.

Infectious Disease Diagnostics Market Regional Insights:

North America is Expected to Dominate the Market Over the Forecast period

  • It is predicted that North America will retain its position and be the largest market for infectious disease diagnostics in the world by the year 2023, as it is powered by increased investment on healthcare facilities and experienced companies. Particularly the United States which is one of the largest markets in the region due to its well-developed healthcare system, growing expenditure on their research and development, and fairly good knowledge about the infectious diseases. From the industry sources, it has been estimated that North America accounted for over 40 percent of the global market size in 2023, which included a higher contribution of the US due to the larger market size, government funded projects, and increased incorporation of enhanced diagnostic devices.
  • A need for faster and more accurate diagnostic tools has emerged steadily in North American region particularly due to COVID-19 and rising instances of antimicrobial resistance. Such agencies as the FDA have also sent regulatory agencies on a drive to fasten the approval processes concerning new diagnostic technologies enhancing market growth. The region’s dominance is also due to the rising strategic partnerships of diagnostics firms, hospitals and research facilities as they drive enhanced regional diagnostics solutions. North America appears to be the biggest market, although consumers in the European and Asia-Pacific regions are expected to proceed to buy more products due to the rising healthcare budgets and increasing knowledge of infectious diseases.

Active Key Players in the Infectious Disease Diagnostics   Market:

  •  Abbott Laboratories (USA)
  •  BD (Becton, Dickinson and Company) (USA)
  •  Beckman Coulter (USA)
  • BioMérieux (France)
  •  Cepheid (USA)
  •  Danaher Corporation (USA)
  •  GenMark Diagnostics (USA)
  •  Grifols (Spain)
  • Hologic, Inc. (USA)
  •  Illumina (USA)
  •  PerkinElmer (USA)
  •  Qiagen (Germany)
  •  Roche Diagnostics (Switzerland)
  •  Siemens Healthineers (Germany)
  •  Thermo Fisher Scientific (USA)
  • Other Active Players.

Infectious Disease Diagnostics  Market

Base Year:

2023

Forecast Period:

2024-2032

Historical Data:

2017 to 2023

Market Size in 2023:

USD 26.74 Billion

Forecast Period 2024-32 CAGR:

 2.4%

Market Size in 2032:

USD 33.10  Billion

Segments Covered:

By Product
  • Instruments
  • (MRSA
  • Streptococcus
  • Clostridium Difficile
  • VRE
  • CRE
  • Respiratory Virus
  • Candida
  • TB and Drug-resistant TB
  • Gastro-intestinal Panel Testing
  • Chlamydia
  • Gonorrhea
  • HPV
  • HIV
  • Hepatitis C
  • Hepatitis B
  • COVID-19
  • Others Infectious Diseases)
  • Reagents
  • (MRSA
  • Streptococcus
  • Clostridium Difficile
  • VRE
  • CRE
  • Respiratory Virus
  • Candida
  • TB and Drug-resistant TB
  • Gastro-intestinal Panel Testing
  • Chlamydia
  • Gonorrhea
  • HPV
  • HIV
  • Hepatitis C
  • Hepatitis B
  • COVID-19
  • Others Infectious Diseases)
  • Software Services
  • (MRSA
  • Streptococcus
  • Clostridium Difficile
  • VRE
  • CRE
  • Respiratory Virus
  • Candida
  • TB and Drug-resistant TB
  • Gastro-intestinal Panel Testing
  • Chlamydia
  • Gonorrhea
  • HPV
  • HIV
  • Hepatitis C
  • Hepatitis B
  • COVID-19
  • Others Infectious Diseases)

By Technology
  • Immunoassay
  • Molecular Diagnostics
  • Polymerase Chain Reaction (PCR)
  • In Situ Hybridization
  • Isothermal Nucleic Acid Amplification Technology (INAAT)
  • Chips and Microarrays
  • Sequencing & NGS
  • Transcription Mediated Amplification
  • Others
  • Microbiology

By Application
  • MRSA
  • Streptococcus
  • Clostridium Difficile
  • VRE
  • CRE
  • Respiratory Virus
  • Candida
  • TB and Drug-resistant TB
  • Gastro-intestinal Panel Testing
  • Chlamydia
  • Gonorrhea
  • HPV
  • HIV
  • Hepatitis C
  • Hepatitis B
  • COVID-19
  • Others Infectious Diseases

Test location
  • Point of Care
  • Central Laboratories
  • Others

By Region
  • North America (U.S., Canada, Mexico)
  • Eastern Europe (Russia, Bulgaria, The Czech Republic, Hungary, Poland, Romania, Rest of Eastern Europe)
  • Western Europe (Germany, UK, France, The Netherlands, Italy, Spain, Rest of Western Europe)
  • Asia Pacific (China, India, Japan, South Korea, Malaysia, Thailand, Vietnam, The Philippines, Australia, New-Zealand, Rest of APAC)
  • Middle East & Africa (Turkiye, Bahrain, Kuwait, Saudi Arabia, Qatar, UAE, Israel, South Africa)
  • South America (Brazil, Argentina, Rest of SA)

Key Market Drivers:
  • Advancements in Molecular Diagnostics and Point-of-Care Testing

Key Market Restraints:
  • High cost of advanced diagnostic solutions.

Key Opportunities:
  • Expanding Market Potential in Emerging Economies

Companies Covered in the report:
  • Abbott Laboratories (USA), Roche Diagnostics (Switzerland), Siemens Healthineers (Germany), Thermo Fisher Scientific (USA), BioMérieux (France) and Other Active Players.

Frequently Asked Questions :

What would be the forecast period in the Infectious Disease Diagnostics Market research report?
The forecast period in the Infectious Disease Diagnostics Market research report is 2024-2032.
Who are the key players in the Infectious Disease Diagnostics Market?
Abbott Laboratories (USA), BD (Becton, Dickinson and Company) (USA), Beckman Coulter (USA), BioM??rieux (France), Cepheid (USA), Danaher Corporation (USA), GenMark Diagnostics (USA), Grifols (Spain), Hologic, Inc. (USA), Illumina (USA), PerkinElmer (USA), Qiagen (Germany), Roche Diagnostics (Switzerland), Siemens Healthineers (Germany), Thermo Fisher Scientific (USA), and Other Active Players.
What are the segments of the Infectious Disease Diagnostics Market?
The Infectious Disease Market is segmented into Product,Technology, Application, Test location and region. By Product, the market is categorized into Instruments(MRSA ,Streptococcus ,Clostridium Difficile ,VRE ,CRE ,Respiratory Virus,Candida ,TB and Drug-resistant TB ,Gastro-intestinal Panel Testing ,Chlamydia ,Gonorrhea ,HPV ,HIV ,Hepatitis C ,HepatitisB,COVID-19 ,Others Infectious Diseases)Reagents(MRSA ,StreptococcusClostridium Difficile ,VRE ,CRE ,Respiratory Virus ,Candida TB and Drug-resistant TB ,Gastro-intestinal Panel Testing ,Chlamydia ,Gonorrhea ,HPV ,HIV ,Hepatitis C ,Hepatitis B ,COVID-19 ,Others Infectious Diseases) ,Software Services (,MRSA ,Streptococcus ,Clostridium Difficile ,VRE ,CRE ,Respiratory Virus ,Candida ,TB and Drug-resistant TB ,,Gastro-intestinal Panel Testing ,Chlamydia ,Gonorrhea ,HPV ,HIV ,Hepatitis C ,Hepatitis B ,COVID-19 ,Others Infectious Diseases) .By Technology ,the market is categorized into Immunoassay ,Molecular Diagnostics ,Polymerase Chain Reaction (PCR) ,In Situ Hybridization ,Isothermal Nucleic Acid Amplification Technology (INAAT) ,Chips and Microarrays ,Sequencing & NGS ,Transcription Mediated Amplification ,Others,Microbiology. By Application, the market is categorized into MRSA ,Streptococcus ,Clostridium Difficile ,VRE ,CRE ,Respiratory Virus ,Candida ,TB and Drug-resistant TB ,Gastro-intestinal Panel Testing ,Chlamydia ,Gonorrhea ,HPV ,HIV ,Hepatitis C ,Hepatitis B ,COVID-19 ,Others Infectious Disease. By Test Location, the market is categorized into Point of Care ,Central Laboratories ,Others. By region, it is analyzed across North America (U.S., Canada, Mexico), Eastern Europe (Russia, Bulgaria, The Czech Republic, Hungary, Poland, Romania, Rest of Eastern Europe), Western Europe (Germany, UK, France, The Netherlands, Italy, Spain, Rest of Western Europe), Asia Pacific (China, India, Japan, South Korea, Malaysia, Thailand, Vietnam, The Philippines, Australia, New-Zealand, Rest of APAC), Middle East & Africa (Turkiye, Bahrain, Kuwait, Saudi Arabia, Qatar, UAE, Israel, South Africa), South America (Brazil, Argentina, Rest of SA)
What is the Infectious Disease Diagnostics Market?
The infectious disease diagnostics market refers to the sector focused on the development and utilization of diagnostic tools and tests used to detect, identify, and monitor infectious diseases caused by pathogens such as bacteria, viruses, fungi, and parasites. These diagnostic solutions, including molecular diagnostics, immunoassays, and microbiology tests, help healthcare professionals identify infections quickly, enabling timely treatment and management. The market plays a crucial role in controlling the spread of infectious diseases, improving patient outcomes, and ensuring public health safety.
How big is the Infectious Disease Diagnostics Market?
Infectious Disease Diagnostics Market Size Was Valued at USD 26.74 Billion in 2023, and is Projected to Reach USD 33.10 Billion by 2032, Growing at a CAGR of 2.4% From 2024-2032.
Request Sample

Related Reports

Services Designed to Meet Your Priorities

Understand your customers' needs so can deliver better services and experiences.

Show more

Subscribe to our Newsletter

Stay in touch with us to get latest news and discount coupons.